SpyGlass Pharma (SGP) investor relations material

Operational achievements and execution

• Closed Series D crossover round and initiated two large phase III pivotal trials for BIM-IOL on schedule in the past year.

• Released three-year data from the First-in-Human trial and one-year follow-up from phase II, both on time.

• Successfully transitioned from private to public company ahead of initial projections, with IPO completed in February.

• Maintains a strong execution track record, with phase III trial enrollment progressing as planned.

Upcoming catalysts and milestones

• Second half of the year will see initiation of first-in-human trial for BIM-DRS, a system potentially offering up to seven years of drug delivery for glaucoma.

• Four-year readout from the first-in-human BIM-IOL study expected later this year, building on strong three-year results.

• Next year includes two-year phase II readout, full phase III enrollment announcement, and top-line phase III data expected in Q4 2027.

Product development and differentiation

• BIM-IOL and BIM-DRS platforms designed for long-term drug delivery, with three-year efficacy exceeding surgeon expectations.

• Four-year and longer-term data demonstrate technology's capability for extended drug release, supporting confidence in future products.

• Phase III product targets three-year duration, aligning with market needs and trial feasibility.